Use of budesonide in severe asthmatics aged 1-3 years
Use of budesonide in severe asthmatics aged 1-3 years
The treatment of severe asthmatics aged 1-3 years with budesonide administered via Nebuhaler and Laerdal facemask was assessed in a six month, double blind, placebo controlled study. Patients were randomised to budesonide (n=20) or placebo (n=20) treatment. Daily symptom scores were recorded by parents and clinic visits occurred every six weeks. Cough scores improved significantly with budesonide: nocturnal and daytime cough scores (0-2) fell by a mean (SEM) of 0 4 (0.2) and 0-5 (0.2); while with placebo the nocturnal score increased by 0.1 (0.2) and daytime score was unchanged at 0.0 (0 2). AUl other data showed improvements for active over placebo treatment. Thirteen children in each group completed six months' treatment. Parents of 25 of these found the delivery system convenient and easy to use. While blinded to treatment it was assessed to be beneficial in nine of 13 receiving budesonide and four of 13 receiving placebo. The Nebuhaler and facemask is an acceptable delivery system for long term asthma treatment. Symptoms are significantly reduced when it is used to give 400-800 ,μg budesonide/day to children aged 1-3 years who cannot use other delivery systems.
351-355
Connett, Gary J.
55d5676c-90d8-46bf-a508-62eded276516
Warde, Catherine
ca227c06-7d14-4f10-9a37-a542d01ff05c
Wooler, Edwina
405eddbb-0468-4089-ba3d-82ca4a4c1c18
Lenney, Warren
16ca6fdd-ab7a-4462-8215-1c6ef991cf1c
September 1993
Connett, Gary J.
55d5676c-90d8-46bf-a508-62eded276516
Warde, Catherine
ca227c06-7d14-4f10-9a37-a542d01ff05c
Wooler, Edwina
405eddbb-0468-4089-ba3d-82ca4a4c1c18
Lenney, Warren
16ca6fdd-ab7a-4462-8215-1c6ef991cf1c
Connett, Gary J., Warde, Catherine, Wooler, Edwina and Lenney, Warren
(1993)
Use of budesonide in severe asthmatics aged 1-3 years.
Archives of Disease in Childhood, 69 (3), .
(doi:10.1136/adc.69.3.351).
Abstract
The treatment of severe asthmatics aged 1-3 years with budesonide administered via Nebuhaler and Laerdal facemask was assessed in a six month, double blind, placebo controlled study. Patients were randomised to budesonide (n=20) or placebo (n=20) treatment. Daily symptom scores were recorded by parents and clinic visits occurred every six weeks. Cough scores improved significantly with budesonide: nocturnal and daytime cough scores (0-2) fell by a mean (SEM) of 0 4 (0.2) and 0-5 (0.2); while with placebo the nocturnal score increased by 0.1 (0.2) and daytime score was unchanged at 0.0 (0 2). AUl other data showed improvements for active over placebo treatment. Thirteen children in each group completed six months' treatment. Parents of 25 of these found the delivery system convenient and easy to use. While blinded to treatment it was assessed to be beneficial in nine of 13 receiving budesonide and four of 13 receiving placebo. The Nebuhaler and facemask is an acceptable delivery system for long term asthma treatment. Symptoms are significantly reduced when it is used to give 400-800 ,μg budesonide/day to children aged 1-3 years who cannot use other delivery systems.
This record has no associated files available for download.
More information
Published date: September 1993
Identifiers
Local EPrints ID: 420677
URI: http://eprints.soton.ac.uk/id/eprint/420677
ISSN: 0003-9888
PURE UUID: 22953f07-c19b-44d1-8e1f-1f819cd599f5
Catalogue record
Date deposited: 11 May 2018 16:30
Last modified: 16 Mar 2024 04:35
Export record
Altmetrics
Contributors
Author:
Gary J. Connett
Author:
Catherine Warde
Author:
Edwina Wooler
Author:
Warren Lenney
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics